March 13, 2012, 11:29 a.m. EDT
COLORADO SPRINGS, Colo., Mar 13, 2012 (BUSINESS WIRE) — Cannabis Science, Inc. CBIS -15.68% , a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is excited to be embarking on a medical marijuana documentary project. Pre-production of this groundbreaking educational film is currently underway.
Many documentaries about marijuana have been made, typically focusing on getting high or the medicinal effects and benefits. Cannabis Science will be first documentary to focus on the science behind medicinal cannabis, including untangling the history of marijuana’s reputation, the improvement it can bring to people’s daily lives, and what breakthroughs could be on the horizon for this emerging industry.
Modern science supports a long list of illnesses that cannabis can treat: Multiple Sclerosis, Cancer, Arthritis, HIV/Aids, Asthma, Alzheimer’s Disease, Anti-aging, Auto Immune Disease, brain trauma (closed head injury), Crohn’s Disease, chronic pain management, Diabetes, digestive illnesses, Gastro Intestinal Reflux Disease (GERD), high blood pressure, Glaucoma, Influenza, Methicillin-Resistant Staphylococcus Aureus (MRSA), Post Traumatic Stress Disorder (PTSD), Tourette Syndrome, and Irritable Bowel Syndrome (IBS), etc. The science gives a foundation for understanding the broad spectrum of benefits that can be achieved by increasing the cannabinoid activity in people suffering from so many illnesses.
Part of the science that will be explored are the various forms marijuana can take as a medication, including edibles, pills, liquids, and strips that dissolve on the tongue. The documentary will investigate how these forms are processed in the body and can reverse or minimized the effects of disease. Cannabis Science is first and foremost a "patient orientated company." Therefore, patients will be interviewed, giving the audience a glimpse at the real, positive benefits the medicine provides for those with chronic illness, as opposed to the prevailing and false belief that marijuana is addictive and even harmful.
Other documentaries showcase marijuana culture, likening it to the popular view of the 1960s and marijuana use running rampant among the hippie population. Cannabis Science’s documentary, however, will show cannabis in a positive light and demonstrate that what has been, and is, taught by prohibitionists is false, and ignores modern science, history, and the voice of patients. The documentary will also focus on the co-founders of Cannabis Science, how the company is working to target critical illnesses, conducting much needed research, and is developing cannabis-based medications. The audience will hear the views of doctors who have discovered for themselves through treating patients the amazing benefits that cannabis based medicines can provide for their patients.
While the main focus of the documentary is not political, learning the truth about the science of cannabinoids will educate the public on the damage caused by prohibition. Patients whose circumstances could have drastically improved and who could have reduced the severity of their illnesses much earlier from medical marijuana will be interviewed. The film will explore the reasons behind the delay in world governments opening up to the idea that medical marijuana is a beneficial reality.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
SOURCE: Cannabis Science, Inc.
Cannabis Science Inc. Dr. Robert J. Melamede, 1-888-889-0888 President & CEO [email protected] www.cannabisscience.com or Robert Kane, 1-561-234-6929 Investor Relations Management [email protected] [email protected] www.cannabisscience.com CONTINUE READING…